[{"id":"9e7aadce-c10d-42e5-89cd-07b8fcf58f56","acronym":"","url":"https://clinicaltrials.gov/study/NCT03896568","created_at":"2021-01-18T19:11:27.737Z","updated_at":"2024-07-02T16:35:17.987Z","phase":"Phase 1","brief_title":"MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma","source_id_and_acronym":"NCT03896568","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IDH1","pipe":" | ","alterations":" IDH wild-type","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tasadenoturev (DNX-2401)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 02/12/2019","start_date":" 02/12/2019","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2024-02-23"},{"id":"0b6c1e9d-8ae3-4c5a-b112-08bf2b62faca","acronym":"TARGET-I","url":"https://clinicaltrials.gov/study/NCT02197169","created_at":"2021-01-18T10:16:26.540Z","updated_at":"2024-07-02T16:37:08.941Z","phase":"Phase 1b","brief_title":"DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors","source_id_and_acronym":"NCT02197169 - TARGET-I","lead_sponsor":"DNAtrix, Inc.","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tasadenoturev (DNX-2401) • Actimmune (interferon gamma-1 b)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 09/11/2014","start_date":" 09/11/2014","primary_txt":" Primary completion: 03/15/2018","primary_completion_date":" 03/15/2018","study_txt":" Completion: 03/15/2018","study_completion_date":" 03/15/2018","last_update_posted":"2018-07-16"}]